LifeLabs Donates $10,000 to Women in Crisis in Honour of the International Day for the Elimination of Violence Against Women and Girls.




LifeLabs Donates $10,000 to Women in Crisis in Honour of the International Day for the Elimination of Violence Against Women and Girls.

Proud to Support a Foundation for a World Free of Gender-Based Violence

Toronto, Ontario, Nov. 25, 2025 (GLOBE NEWSWIRE) — LifeLabs, Canada’s leading provider of medical diagnostic services, is proud to donate $10,000 to Guelph-Wellington Women in Crisis, a charitable social purpose organization that provides safety, support, information, and advocacy to women and gender-diverse people, and their children.  

November 25th is the International Day for the Elimination of Violence Against Women. Tragically, violence against women, gender-diverse people and girls remains one of the most prevalent and pervasive human rights violations in the world. Globally, almost one in three women has been subjected to physical assault at least once in their lives with incidents of intimate partner violence reported to police rising by 19 per cent between 2014 and 2022. In Ontario alone, the number of femicides in 2024 was a horrifying 62 individuals. This year, the day will focus on ending digital violence against women and girls, a form of violence that is increasing dramatically. 

In the face of these stark statistics, we are reminded of the strength of survivors of gender-based violence and the importance of working to end it. 

LifeLabs is proud to stand alongside survivors and is committed to doing our part to lay the foundation for a world that is free of gender-based violence. 

“On this International Day for the Elimination of Violence Against Women, LifeLabs joins the call to end gender-based violence,” said Charles Brown, CEO and President of LifeLabs. “We are inspired by the work being done by Women in Crisis and are proud to support their mission.” 

“We are deeply grateful to LifeLabs for their generous support. When corporations invest in local organizations, they help build stronger, healthier communities, both for their own employees and for the wider community of family, friends and neighbours. This partnership between LifeLabs and us will enhance support for those impacted by gender-based violence. This gift is an investment that will help ensure vital, often life-saving services, remain accessible to those who need them most,” said Sly Castaldi, Executive Director of Guelph-Wellington Women in Crisis. 

To survivors and to all those who work to build connection and care in the communities we serve, thank you. We are honoured to walk alongside you. 

For 24-hour anonymous support, you can reach the Women in Crisis Crisis Line at 519-836-5710 or 1-800-265-7233. If you are in an emergency situation, please call 9-1-1 (in Canada) for immediate services in your area. If you or someone you know is experiencing gender-based violence, consult the list of additional support services for people affected by gender-based violence. 

About LifeLabs 

Empowering healthier Canadians for over 60 years, LifeLabs was founded in Canada and remains dedicated to serving Canadian communities. As Canada’s leading provider of laboratory diagnostic information and digital health connectivity systems, LifeLabs enables patients and healthcare practitioners to diagnose, treat, monitor, and prevent disease. We support over 15 million patient visits annually and conduct over 140 million laboratory tests through leading-edge technologies and our 6,500 talented and dedicated employees located across Canada. We are a committed innovator in supporting Canadians to live healthier lives, operating Canada’s first commercial genetics lab and the country’s largest online patient portal, with more than 9 million Canadians receiving their results online. LifeLabs has been named one of Canada’s Best Employers (2021, 2022 and 2023) and Best Employers for Diversity (2022 and 2023) by Forbes and recognized for having an award-winning Mental Health Program from Benefits Canada. 

About Guelph-Wellington Women in Crisis 

Guelph-Wellington Women in Crisis is a feminist, community-based organization that is fiercely committed to safety, advocacy, education, and support for women and gender-diverse people impacted by gender-based violence (GBV). For nearly 50 years, we have been a leader in both prevention and intervention, helping survivors rebuild their lives while working to create lasting systemic change. Our Programs & Services include: 24-hour Crisis Line, emergency residential shelter at Marianne’s Place (28 beds), four counselling & support service programs in Guelph [Transitional and Housing Support, Family Court Support, Anti-Human Trafficking, Sexual Assault Centre] and Rural Women’s Support Program offices in Fergus, Mount Forest, Palmerston & Erin. 

Attachment

• LifeLabs and Guelph-Wellington Women in Crisis

CONTACT: Media Team
LifeLabs
media@lifelabs.com

Branded Legacy Announces Strong Revenues from Newly Acquired Pau Hana Subsidiary




Branded Legacy Announces Strong Revenues from Newly Acquired Pau Hana Subsidiary

Pau Hana Plans Ambitious Expansion Roadmap and New Location Acquisitions in the Pipeline

MELBOURNE, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) — via IBN — Branded Legacy, Inc. (OTC:BLEG), a leader in innovative addiction treatment and harm reduction solutions, today announced that its newly acquired subsidiary, Pau Hana, posted strong third quarter revenues of just over one hundred and twenty-five thousand dollars ($125,000.00). Branded Legacy intends to aggressively scale this division throughout 2026 and beyond through a targeted roll-up strategy of additional high-performing locations. Each future acquisition will follow the Pau Hana blueprint: integrating established, cash-flow-positive kava bars into the portfolio to immediately layer on new streams of daily retail revenue while leveraging centralized sourcing, branding, and operational efficiencies to boost margins. This repeatable acquisition model is designed to drive exponential, compounding revenue growth, positioning Branded Legacy as a dominant consolidator in the multi-billion-dollar sober-social and functional beverage movement.

Branded Legacy, Inc. has strategically diversified its portfolio with the strategic acquisition of Pau Hana, marking its bold entry into the fast-growing kava and wellness lounge sector. This milestone acquisition instantly unlocked daily, recurring revenue streams from Pau Hana’s thriving retail operation in West Melbourne, Florida, a location that has consistently generated strong cash flow since its 2023 launch through premium kava sales, specialty mocktails, events, and merchandise. Unlike one-time product sales, Pau Hana delivers predictable, high-margin daily income from foot traffic, repeat clientele, and a loyal membership base, providing Branded Legacy with a stable new revenue pillar that significantly enhances overall financial performance and shareholder value.

As Pau Hana looks ahead to 2026, the team is channeling its explosive growth since opening in West Melbourne, Florida, in January 2023 into a bold expansion strategy designed to bring the island-inspired, alcohol-free relaxation revolution to new horizons. With a meticulously planned roadmap that includes opening three to five new locations across high-potential markets in Florida, targeting vibrant communities in and around Central Florida. The brand aims to scale its footprint by 150% within the year, capitalizing on the surging demand for wellness-focused social spaces. This organic growth will feature flagship venues that blend traditional kava rituals with modern amenities like expanded event programming and pet-friendly lounges, all while maintaining the core commitment to noble kava varieties that deliver anxiety-reducing calm and euphoric vibes without the regrets of traditional nightlife.

Branded Legacy intends to aggressively scale its kava bar division throughout 2026 and beyond through a targeted roll-up strategy of additional high-performing locations. Each future acquisition will follow the Pau Hana blueprint: integrating established, cash-flow-positive kava bars into the portfolio to immediately layer on new streams of daily retail revenue while leveraging centralized sourcing, branding, and operational efficiencies to boost margins. This repeatable acquisition model is designed to drive exponential, compounding revenue growth, positioning Branded Legacy as a dominant consolidator in the multi-billion-dollar sober-social and functional beverage movement.

Branded Legacy recognized the benefits of Kava and how Kava’s appeal lies largely in its well-documented calming and mood-enhancing effects, which come primarily from active compounds called kavalactones. In recent years, kava bars have rapidly emerged as a popular social destination across the United States and beyond, evolving from a traditional Pacific Island ritual into a modern wellness and nightlife alternative. Cities like South Florida, Southern California, Colorado, and North Carolina now host dozens of dedicated kava bars. Unlike traditional bars, kava venues promote a relaxed, alcohol-free environment where patrons gather to drink “shells” of the earthy, tongue-numbing beverage while playing games, listening to live music, or simply unwinding. The trend has been fueled by growing interest in natural alternatives to alcohol, especially among younger adults seeking social spaces that don’t revolve around drinking or late-night partying.

About Pau Hana.

Nestled at the vibrant intersection of U.S. Highway 192 and Wickham Road in West Melbourne, Florida, Pau Hana Kava Bar opened its doors in January 2023 as a welcoming haven for those seeking a mindful escape from the everyday hustle. Drawing inspiration from the Hawaiian phrase “Pau Hana,” which celebrates the sweet relief of the workday’s end, this pet-friendly spot embodies the spirit of community and relaxation in a sophisticated, alcohol-free environment. Founded with a passion for natural wellness, Pau Hana has quickly become a local favorite, offering a refreshing alternative to traditional bars where patrons can unwind without the haze of hangovers or regrets. Our commitment to quality shines through in every carefully crafted beverage, fostering connections among friends, families, and newcomers alike in a space designed for genuine, feel-good vibes. Please visit: https://pauhanakava.com/

Branded Legacy recently announced that it’s subsidiary BioLegacy Evaluative Group Inc., has initiated engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform. This milestone marks a significant step toward scalable production of its groundbreaking single-use device, designed to deliver rapid, consistent, and reliable therapeutics, including its flagship inhaled naloxone program.

About BioLegacy Evaluative Group, Inc.
BioLegacy Evaluative Group Inc. is a life sciences company dedicated to developing innovative therapies and devices addressing urgent global health challenges. With strategic partnerships at McMaster University and Stanford University, and a newly acquired GMP-compliant manufacturing facility, BioLegacy is positioned to deliver scalable, cost-effective solutions in areas of high unmet need.

About Pau Hana

Florida, Pau Hana Kava Bar opened its doors in January 2023 as a welcoming haven for those seeking a mindful escape from the everyday hustle. Drawing inspiration from the Hawaiian phrase “Pau Hana,” which celebrates the sweet relief of the workday’s end, this pet-friendly spot embodies the spirit of community and relaxation in a sophisticated, alcohol-free environment.

About Branded Legacy, Inc.

Branded Legacy, Inc. (OTC:BLEG) is a forward-thinking holdings company dedicated to pioneering solutions in addiction treatment and harm reduction. Through its subsidiary, BioLegacy Evaluative Group, and strategic collaborations with leading institutions like McMaster University and Stanford University, the company drives transformative research and innovation. With a state-of-the-art GMP manufacturing facility in Vancouver, Branded Legacy leverages advanced production capabilities to deliver cutting-edge products, positioning itself as a leader in addressing critical public health challenges. For more information, visit www.brandedlegacy.com.

Investor Relations

Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.

InvestorWire Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

LifeLabs Donates $10,000 to Women in Crisis in Honour of the International Day for the Elimination of Violence Against Women and Girls.




LifeLabs Donates $10,000 to Women in Crisis in Honour of the International Day for the Elimination of Violence Against Women and Girls.

Proud to Support a Foundation for a World Free of Gender-Based Violence

Toronto, Ontario, Nov. 25, 2025 (GLOBE NEWSWIRE) — LifeLabs, Canada’s leading provider of medical diagnostic services, is proud to donate $10,000 to Guelph-Wellington Women in Crisis, a charitable social purpose organization that provides safety, support, information, and advocacy to women and gender-diverse people, and their children.  

November 25th is the International Day for the Elimination of Violence Against Women. Tragically, violence against women, gender-diverse people and girls remains one of the most prevalent and pervasive human rights violations in the world. Globally, almost one in three women has been subjected to physical assault at least once in their lives with incidents of intimate partner violence reported to police rising by 19 per cent between 2014 and 2022. In Ontario alone, the number of femicides in 2024 was a horrifying 62 individuals. This year, the day will focus on ending digital violence against women and girls, a form of violence that is increasing dramatically. 

In the face of these stark statistics, we are reminded of the strength of survivors of gender-based violence and the importance of working to end it. 

LifeLabs is proud to stand alongside survivors and is committed to doing our part to lay the foundation for a world that is free of gender-based violence. 

“On this International Day for the Elimination of Violence Against Women, LifeLabs joins the call to end gender-based violence,” said Charles Brown, CEO and President of LifeLabs. “We are inspired by the work being done by Women in Crisis and are proud to support their mission.” 

“We are deeply grateful to LifeLabs for their generous support. When corporations invest in local organizations, they help build stronger, healthier communities, both for their own employees and for the wider community of family, friends and neighbours. This partnership between LifeLabs and us will enhance support for those impacted by gender-based violence. This gift is an investment that will help ensure vital, often life-saving services, remain accessible to those who need them most,” said Sly Castaldi, Executive Director of Guelph-Wellington Women in Crisis. 

To survivors and to all those who work to build connection and care in the communities we serve, thank you. We are honoured to walk alongside you. 

For 24-hour anonymous support, you can reach the Women in Crisis Crisis Line at 519-836-5710 or 1-800-265-7233. If you are in an emergency situation, please call 9-1-1 (in Canada) for immediate services in your area. If you or someone you know is experiencing gender-based violence, consult the list of additional support services for people affected by gender-based violence. 

About LifeLabs 

Empowering healthier Canadians for over 60 years, LifeLabs was founded in Canada and remains dedicated to serving Canadian communities. As Canada’s leading provider of laboratory diagnostic information and digital health connectivity systems, LifeLabs enables patients and healthcare practitioners to diagnose, treat, monitor, and prevent disease. We support over 15 million patient visits annually and conduct over 140 million laboratory tests through leading-edge technologies and our 6,500 talented and dedicated employees located across Canada. We are a committed innovator in supporting Canadians to live healthier lives, operating Canada’s first commercial genetics lab and the country’s largest online patient portal, with more than 9 million Canadians receiving their results online. LifeLabs has been named one of Canada’s Best Employers (2021, 2022 and 2023) and Best Employers for Diversity (2022 and 2023) by Forbes and recognized for having an award-winning Mental Health Program from Benefits Canada. 

About Guelph-Wellington Women in Crisis 

Guelph-Wellington Women in Crisis is a feminist, community-based organization that is fiercely committed to safety, advocacy, education, and support for women and gender-diverse people impacted by gender-based violence (GBV). For nearly 50 years, we have been a leader in both prevention and intervention, helping survivors rebuild their lives while working to create lasting systemic change. Our Programs & Services include: 24-hour Crisis Line, emergency residential shelter at Marianne’s Place (28 beds), four counselling & support service programs in Guelph [Transitional and Housing Support, Family Court Support, Anti-Human Trafficking, Sexual Assault Centre] and Rural Women’s Support Program offices in Fergus, Mount Forest, Palmerston & Erin. 

Attachment

• LifeLabs and Guelph-Wellington Women in Crisis

CONTACT: Media Team
LifeLabs
media@lifelabs.com

San Diego’s Premier Neurological-Spine Care Clinic Launches Massive Holiday NUCCA Promotion: 50% Off for New Patients Through Dec. 31




San Diego’s Premier Neurological-Spine Care Clinic Launches Massive Holiday NUCCA Promotion: 50% Off for New Patients Through Dec. 31

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) — Just in time for the year-end wellness rush, Origin Modern Health & Wellness is offering 50 % off its signature evaluation and care plan for new patients through December 31, 2025. The limited-time offer includes a comprehensive body exam with posture scans and nervous system tests, advanced 3D imaging, and a custom Nervous System Correction Care Plan using the gentle yet powerful NUCCA Protocol as part of their MIMI™ (Minimal Intervention Maximal Impact) Method. To take advantage of this life-changing opportunity, simply mention “MIMI” when calling or scheduling an appointment online.

This announcement comes as many are seeking meaningful solutions for persistent headaches, vertigo, chronic pain, and nervous system imbalances. Origin’s advanced spine-and-nervous-system approach offers a clear path forward: no cracking, popping, or twisting—just precision upper-cervical alignment to help the brain-body connection reset and thrive.

Regarding the importance and timing of this promotion, Dr. Soham states: “As the seasons change so does your body, making sure you are well equipped and resourced through every season… this time of year we are eating more, drinking more and sleeping less.”

Why This Matters Now

As the holidays approach, stress, travel, and seasonal shifts often exacerbate underlying nervous system issues. Many patients at Origin report having “tried everything” but still feel dismissed or stuck. The 50 % holiday promotion removes a major barrier for those ready to take action in the final weeks of the year and start 2026 aligned, empowered, and healthy.

Dr. Vivek Soham, DC, CME, MNPhys, BSc—Founder and lead practitioner at Origin—makes clear: “True relief starts when your foundation is right… when your brain and body can finally communicate without interference.” This small shift makes a big difference. It opens a direct line between your brain and body, allowing your system to reset, self-regulate, and begin real healing. When you fix the root, everything else starts to align. That’s the true relief patients have been looking for.

Community Leadership & Local Credibility

Dr. Soham is deeply rooted in the San Diego community. He is the driving force behind Origin’s “Guardian Initiative,” which supports veterans and first-responders through charity events and wellness outreach—recently featured on local media. (See CBS8’s coverage of the Guardian Classic Charity Golf Tournament benefiting those groups.)

His commitment to those who serve and protect underscores the values of service, integrity and excellence that underpin the clinic’s mission. Patients are not just clients—they become part of a community that grows stronger together.

“Serving veterans hits home for me with my wife and close friend,” says Dr. Soham. “Seeing my loved ones suffering from migraines, vertigo and debilitating neurological symptoms throughout my life has been the guiding star to providing real solutions at the highest level, not just temporary band aids.”

What You Get With the Holiday Promotion

New patients booking by December 31 will receive:

• A comprehensive body exam including posture scans and nervous system testing
• Advanced 3D imaging to visualise spinal alignment and nervous-system integrity
• A complete custom Nervous System Correction Care Plan, tailored specifically to your needs and goals
• All at 50 % off the standard new-patient package

Spaces are limited, and this offer will not be extended beyond December 31, 2025. Patients are encouraged to call (858) 432-3072 or visit originmodernhealth.janeapp.com to secure their spot—both the Ocean Beach and Carlsbad locations are participating. Simply mention “MIMI” when calling or scheduling an appointment online to take advantage of this life-changing opportunity!

Ideal Candidates

This program is designed for anyone who is:

• Tired of chronic migraines, dizziness/vertigo, spinal pain or neurologic-system issues
• Ready to access next-level care that looks beyond symptoms and focuses on root-cause nervous system alignment
• Seeking to start the new year with renewed health, vitality and clarity

As Dr. Soham puts it: “When your foundation is right, you’re free to thrive.”

About Origin Modern Health & Wellness

Origin Modern Health & Wellness brings advanced upper cervical care—via the NUCCA method—to San Diego, helping over 870 lives changed, doubling energy levels within three months and achieving high rates of migraine and blood-pressure relief. There are two convenient locations: 2204 Sunset Cliffs Blvd., Ste 202, San Diego 92107 (Ocean Beach) and 7220 Avenida Encinas #120, Carlsbad 92011.

Media Contacts

For interviews, patient success stories or images/footage of the clinic:
Contact: info@camppublicrelations.com
Website: www.CampPR.com

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference




UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the Piper Sandler 37^th Annual Healthcare Conference to take place on December 2-4, 2025.

Piper Sandler 37th Annual Healthcare Conference

Webcasts from the conferences will also be available on UroGen’s Investor Relations website. A replay will be available on the site for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and second product (mitomycin) for intravesical solution for adult patients with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference




UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the Piper Sandler 37^th Annual Healthcare Conference to take place on December 2-4, 2025.

Piper Sandler 37th Annual Healthcare Conference

Webcasts from the conferences will also be available on UroGen’s Investor Relations website. A replay will be available on the site for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and second product (mitomycin) for intravesical solution for adult patients with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083

Septerna to Participate in 8th Annual Evercore Healthcare Conference




Septerna to Participate in 8th Annual Evercore Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) — Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a fireside chat at the 8^th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 a.m. ET in Coral Gables, Florida.

A live webcast of the presentation will be available in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation.

About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com

Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference




Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Aclaris’ Chief Executive Officer and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference in New York City. The discussion will take place on Tuesday December 2, 2025 at 11:00 AM EST.

A live and archived webcast will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com

Septerna to Participate in 8th Annual Evercore Healthcare Conference




Septerna to Participate in 8th Annual Evercore Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) — Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a fireside chat at the 8^th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 a.m. ET in Coral Gables, Florida.

A live webcast of the presentation will be available in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation.

About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com

Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference




Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Aclaris’ Chief Executive Officer and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference in New York City. The discussion will take place on Tuesday December 2, 2025 at 11:00 AM EST.

A live and archived webcast will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com